image description

Tag: Target Identification in Lupus

New Approach to Treating Lupus Nephritis

February 6, 2019 Scientists partly funded by the Lupus Research Alliance have found a potential new way to protect the kidneys in patients with lupus. A study led by Dr. Vicki Rubin Kelley of Brigham and Women’s Hospital in Boston, Massachusetts, suggests that blocking a molecule made by some cells in the kidney could reduce […] Read More

2017-18 Research Portfolio Summary

June 5, 2018 The Lupus Research Alliance is driven by one central goal — to improve the lives of people living with the disease, today and in the long term. We believe that scientific research is the most powerful way we can achieve this goal. Further, we believe that by both pushing the limits of scientific exploration and […] Read More

2017: A Year of Great Triumph for Lupus

Nov. 28, 2017. Thanks to you, the Lupus Research Alliance continues to make game-changing gains in advancing the basic understanding of lupus … while giving hope to millions of people that a potential cure is within reach. We Invested in Innovative Research The Lupus Research Alliance gave 19 scientists the means to bring their ideas […] Read More

LRA Grant Leads to New Drug Candidate RSLV-132

May 10, 2019 Grant support from the Lupus Research Alliance (then ALR) supported early work that led to a potential new drug, RSLV-132. In lupus, antibodies can target DNA’s chemical cousin RNA, which performs a variety of jobs in cells. When these antibodies encounter an RNA molecule, they attach to it, forming clusters that can […] Read More

Skin Molecules Promote Cutaneous Lupus

June 24, 2019 Patients with cutaneous lupus develop rashes because immune cells move into the skin and cause inflammation. With a Target Identification in Lupus (TIL) grant from the Lupus Research Alliance, Dr. Jillian Richmond of the University of Massachusetts Medical School and colleagues found what lures the immune cells into the skin of people […] Read More

Lupus Research Alliance Announces New Grants For Translational Research

Jan. 10, 2018 Lupus Research Alliance Announces New Grants for Translational Research Seven Outstanding Investigators Chosen for Prestigious Lupus Research Grants The Lupus Research Alliance is proud to announce the recipients of its Target Identification in Lupus (TIL) grants designed to move research discoveries quickly from the laboratory to the patient’s bedside. Seven outstanding scientists […] Read More

New Study Partly Funded by LRA Reveals Novel Lupus Drug Targets

NEW YORK, NY – May 29. Researchers partly funded by the Lupus Research Alliance (LRA) have found possible new targets for drugs to treat lupus after snapping the first close-up of a molecule that promotes inflammation. The molecule that Target Identification in Lupus (TIL) grant recipient Dr. Roger Greenberg at University of Pennsylvania and Dr. […] Read More

Celebrate Clinical Trials Day May 20!

May 20, 2019 It’s Clinical Trials Day when the Lupus Research Alliance recognizes all the people we support who advance clinical research – scientists who identify and develop potential ways to diagnose, monitor and treat lupus,  researchers who design and conduct the studies to test these methods, and the volunteers who take part in the […] Read More

The Numbers Add Up to 20 Years of Extraordinary Progress

May 1, 2019 The Lupus Research Alliance is honored to serve the lupus community as the global leader in lupus research, both in the resources we deploy and the results we deliver.  Collectively we have invested more than $200 million in over 500 grants selected by a multi-level peer review process led by world-class luminaries […] Read More

LRA-funded Research Backs New Lupus Nephritis Clinical Trial

February 28, 2019 The biotechnology company Equillium Inc. just announced plans for a Phase 1 study to test the investigational monoclonal antibody EQ001 as a potential treatment for lupus nephritis (LN) that has not responded to existing treatment. The basis for this study is in part due to work conducted by Dr. Chandra Mohan that […] Read More